Rochester,NY 8/15/2009 1:43:41 AM
CombinatoRx, Incorporated.,CRXX-Clinical Data, CombinatoRx strike an agreement
CombinatoRx, Incorporated
A subsidiary of Clinical Data Inc. and CombinatoRx Inc. have signed a licensing deal valued at up to $257 million in milestone and royalty payments.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
The team-work calls for Newton, Mass.-based Clinical Data to license its multiple myeloma treatment, adenosine A2A agonist ATL313, to CombinatoRx. In return, Cambridge, Mass.-based CombinatoRx will take care preclinical and clinical growth of the treatment for B-cell malignancies. Clinical Data also can exercise a co-development option following Phase 2a study outcomes.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
